157 related articles for article (PubMed ID: 35737885)
1. Cardiometabolic multimorbidity is common among patients with psoriasis and is associated with poorer outcomes compared to those without comorbidity.
Enos CW; Ramos VL; McLean RR; Lin TC; Foster N; Dube B; Van Voorhees AS
J Dermatolog Treat; 2022 Nov; 33(7):2975-2982. PubMed ID: 35737885
[TBL] [Abstract][Full Text] [Related]
2. Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6 months: A prospective analysis in Corrona Psoriasis Registry.
Enos CW; Ramos VL; McLean RR; Lin TC; Foster N; Dube B; Van Voorhees AS
J Am Acad Dermatol; 2022 Jan; 86(1):68-76. PubMed ID: 34256035
[TBL] [Abstract][Full Text] [Related]
3. Persistence of second-line biologics in psoriasis after first-line biologic failure: a nationwide cohort study from the French health insurance database (SNDS).
Marcombes C; Penso L; Weill A; Dray-Spira R; Zureik M; Sbidian E
Br J Dermatol; 2023 Oct; 189(5):561-568. PubMed ID: 37479503
[TBL] [Abstract][Full Text] [Related]
4. Are interleukin 17 and interleukin 23 inhibitors associated with malignancies?-Insights from an international population-based study.
Kridin K; Abdelghaffar M; Mruwat N; Ludwig RJ; Thaçi D
J Eur Acad Dermatol Venereol; 2024 Feb; 38(2):315-324. PubMed ID: 37730962
[TBL] [Abstract][Full Text] [Related]
5. Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: The Corrona Psoriasis Registry.
Lockshin B; Cronin A; Harrison RW; McLean RR; Anatale-Tardiff L; Burge R; Zhu B; Malatestinic WN; Atiya B; Murage MJ; Gallo G; Strober B; Van Voorhees A
Dermatol Ther; 2021 Mar; 34(2):e14808. PubMed ID: 33491259
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the risk of infections under interleukin 23 and interleukin 17 inhibitors relative to tumour necrosis factor inhibitors - A population-based study.
Kridin K; Zirpel H; Mruwat N; Ludwig RJ; Thaci D
J Eur Acad Dermatol Venereol; 2023 Nov; 37(11):2319-2326. PubMed ID: 37466275
[TBL] [Abstract][Full Text] [Related]
7. Treatment Persistence and Adherence Among Patients With Psoriatic Arthritis Who Initiated Targeted Immune Modulators in the US: A Retrospective Cohort Study.
Walsh JA; Cai Q; Lin I; Pericone CD; Chakravarty SD
Adv Ther; 2021 May; 38(5):2353-2364. PubMed ID: 33759081
[TBL] [Abstract][Full Text] [Related]
8. Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry.
Strober B; Karki C; Mason M; Guo N; Holmgren SH; Greenberg JD; Lebwohl M
J Am Acad Dermatol; 2018 Feb; 78(2):323-332. PubMed ID: 29051036
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of Biologic Use in Asian Compared with Non-Hispanic White Adult Psoriasis Patients from the CorEvitas Psoriasis Registry.
Yu C; Wang G; Burge RT; Ye E; Dou G; Li J; Harrison RW; McLean RR; Kerti SJ; Bagel J
Dermatol Ther (Heidelb); 2023 Jan; 13(1):187-206. PubMed ID: 36385699
[TBL] [Abstract][Full Text] [Related]
10. Risk of Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis/Ankylosing Spondylitis Initiating Interleukin-17 Inhibitors: A Nationwide Population-Based Study Using the French National Health Data System.
Penso L; Bergqvist C; Meyer A; Herlemont P; Weill A; Zureik M; Dray-Spira R; Sbidian E
Arthritis Rheumatol; 2022 Feb; 74(2):244-252. PubMed ID: 34279061
[TBL] [Abstract][Full Text] [Related]
11. Starting of biological disease modifying antirheumatic drugs may be postponed in rheumatoid arthritis patients with multimorbidity: Single center real life results.
Armagan B; Sari A; Erden A; Kilic L; Erdat EC; Kilickap S; Kiraz S; Bilgen SA; Karadag O; Akdogan A; Ertenli I; Kalyoncu U
Medicine (Baltimore); 2018 Mar; 97(13):e9930. PubMed ID: 29595700
[TBL] [Abstract][Full Text] [Related]
12. Association of Ustekinumab vs TNF Inhibitor Therapy With Risk of Atrial Fibrillation and Cardiovascular Events in Patients With Psoriasis or Psoriatic Arthritis.
Lee MP; Desai RJ; Jin Y; Brill G; Ogdie A; Kim SC
JAMA Dermatol; 2019 Jun; 155(6):700-707. PubMed ID: 30916734
[TBL] [Abstract][Full Text] [Related]
13. Does previous use of tumour necrosis inhibitors change the therapeutic effect of interleukin (IL)-17 or IL-12/23 inhibitors on psoriasis and psoriatic arthritis? Results of a systematic review.
Xie Y; Liu Y
Clin Exp Dermatol; 2022 Sep; 47(9):1627-1635. PubMed ID: 35466472
[TBL] [Abstract][Full Text] [Related]
14. Real-World Evidence Assessing Psoriatic Arthritis by Disease Domain: An Evaluation of the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.
Mease PJ; O'Brien J; Middaugh N; Kricorian G; Stryker S; Collier DH; Ogdie A
ACR Open Rheumatol; 2023 Aug; 5(8):388-398. PubMed ID: 37356824
[TBL] [Abstract][Full Text] [Related]
15. Effects of biologic agents and other disease-modifying antirheumatic drugs on cardiovascular outcomes in psoriasis and psoriatic arthritis: a systematic review.
Armstrong AW; Brezinski EA; Follansbee MR; Armstrong EJ
Curr Pharm Des; 2014; 20(4):500-12. PubMed ID: 23565631
[TBL] [Abstract][Full Text] [Related]
16. Biologics targeting IL-17 and IL-23 maintain stability in patients with psoriasis during COVID-19 infection: a case-control study.
Huang D; Yu Y; Lu J; Tan F; Shi Y
Front Med (Lausanne); 2023; 10():1280965. PubMed ID: 38020100
[TBL] [Abstract][Full Text] [Related]
17. Clinical Controversies in Psoriatic Disease: The Use of IL-17i/IL-23i Versus TNFi as First-line Advanced Therapy in Psoriatic Arthritis.
Jadon DR; Kavanaugh A; Leung YY
J Rheumatol; 2022 Jun; 49(6 Suppl 1):26-31. PubMed ID: 35169062
[TBL] [Abstract][Full Text] [Related]
18. Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis.
Acosta Felquer ML; LoGiudice L; Galimberti ML; Rosa J; Mazzuoccolo L; Soriano ER
Ann Rheum Dis; 2022 Jan; 81(1):74-79. PubMed ID: 34281904
[TBL] [Abstract][Full Text] [Related]
19. Psoriasis Severity, Comorbidities, and Treatment Response Differ among Geographic Regions in the United States.
Enos CW; O'Connell KA; Harrison RW; McLean RR; Dube B; Van Voorhees AS
JID Innov; 2021 Jun; 1(2):100025. PubMed ID: 34909720
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular comorbidities of psoriasis and psoriatic arthritis: a report from the GRAPPA 2012 annual meeting.
Armstrong AW; Gelfand JM; Boehncke WH; Armstrong EJ
J Rheumatol; 2013 Aug; 40(8):1434-7. PubMed ID: 23908540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
